Blood Tests May Identify Patients Less Likely to Benefit from Hormone Therapies

Blood Tests May Identify Patients Less Likely to Benefit from Hormone Therapies
Two new blood tests that detect a variant of the androgen receptor — a protein that binds male hormones called androgens — may help to predict those advanced prostate cancer patients who would not benefit from anti-androgen therapies, new research suggests. The tests, which are called “liquid biopsies,” may help guide care toward more effective treatments. The research, “The PROPHECY trial: Multicenter prospective trial of circulating tumor cell (CTC) AR-V7 detection in men with mCRPC receiving abiraterone (A) or enzalut
Subscribe or to access all post and page content.

Leave a Comment

Your email address will not be published. Required fields are marked *